☰

Christopher A. Jedeszko, Ph.D. - Publications

Affiliations: 
2009 Pharmacology Wayne State University, Detroit, MI, United States 
Area:
Cell Biology
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Jedeszko C, Paez-Ribes M, Di Desidero T, Man S, Lee CR, Xu P, Bjarnason GA, Bocci G, Kerbel RS. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Science Translational Medicine. 7: 282ra50. PMID 25855496 DOI: 10.1126/Scitranslmed.3010722  0.426
2014 Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. Embo Molecular Medicine. 6: 1561-76. PMID 25361689 DOI: 10.15252/Emmm.201403989  0.343
2013 Di Matteo P, Hackl C, Jedeszko C, Valentinis B, Bordignon C, Traversari C, Kerbel RS, Rizzardi GP. NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells. British Journal of Cancer. 109: 360-9. PMID 23828516 DOI: 10.1038/Bjc.2013.347  0.311
2013 Caglič D, Repnik U, Jedeszko C, Kosec G, Miniejew C, Kindermann M, Vasiljeva O, Turk V, Wendt KU, Sloane BF, Goldring MB, Turk B. The proinflammatory cytokines interleukin-1α and tumor necrosis factor α promote the expression and secretion of proteolytically active cathepsin S from human chondrocytes. Biological Chemistry. 394: 307-16. PMID 23152404 DOI: 10.1515/Hsz-2012-0283  0.563
2012 Matteo PD, Hackl C, Jedeszko C, Porcellini S, Valentinis B, Bordignon C, Traversari C, Kerbel RS, Rizzardi G. Abstract 4381: The novel direct-acting vascular targeting agent NGR-TNF exertsin vivoantitumor activity by inducing endothelial and tumor cell death in the absence of proangiogenic bone-marrow derived cell recruitment Cancer Research. 72: 4381-4381. DOI: 10.1158/1538-7445.Am2012-4381  0.44
2012 Ebos JML, Lee CR, Cruz-Munoz W, Jedeszko C, Kerbel RS. Abstract 1375: Contrasting effects of VEGF pathway inhibitors in primary and metastatic disease using perioperative neoadjuvant mouse models Cancer Research. 72: 1375-1375. DOI: 10.1158/1538-7445.Am2012-1375  0.397
2011 Matteo PD, Hackl C, Jedeszko C, Valentinis B, Bordignon C, Traversari C, Kerbel RS, Rizzardi G. Abstract 4249: NGR-TNF, a novel direct-acting vascular targeting agent, does not induce “cytokine-rebound” recruitment of pro-angiogenic bone-marrow derived cells Cancer Research. 71: 4249-4249. DOI: 10.1158/1538-7445.Am2011-4249  0.416
2009 Jedeszko C, Victor BC, Podgorski I, Sloane BF. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Research. 69: 9148-55. PMID 19920187 DOI: 10.1158/0008-5472.Can-09-1043  0.648
2009 Sameni M, Cavallo-Medved D, Dosescu J, Jedeszko C, Moin K, Mullins SR, Olive MB, Rudy D, Sloane BF. Imaging and quantifying the dynamics of tumor-associated proteolysis Clinical and Experimental Metastasis. 26: 299-309. PMID 19082919 DOI: 10.1007/S10585-008-9218-7  0.665
2008 Jedeszko C, Sameni M, Olive MB, Moin K, Sloane BF. Visualizing protease activity in living cells: from two dimensions to four dimensions. Current Protocols in Cell Biology / Editorial Board, Juan S. Bonifacino ... [Et Al.]. Unit 4.20. PMID 18551423 DOI: 10.1002/0471143030.Cb0420S39  0.62
2005 Blum G, Mullins SR, Keren K, Fonovic M, Jedeszko C, Rice MJ, Sloane BF, Bogyo M. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nature Chemical Biology. 1: 203-9. PMID 16408036 DOI: 10.1038/Nchembio728  0.645
2005 Thomas T, Jordan K, Simek J, Shao Q, Jedeszko C, Walton P, Laird DW. Mechanisms of Cx43 and Cx26 transport to the plasma membrane and gap junction regeneration. Journal of Cell Science. 118: 4451-62. PMID 16159960 DOI: 10.1242/Jcs.02569  0.355
2005 Brocard CB, Boucher KK, Jedeszko C, Kim PK, Walton PA. Requirement for microtubules and dynein motors in the earliest stages of peroxisome biogenesis. Traffic (Copenhagen, Denmark). 6: 386-95. PMID 15813749 DOI: 10.1111/J.1600-0854.2005.00283.X  0.359
2005 Podgorski I, Linebaugh BE, Sameni M, Jedeszko C, Bhagat S, Cher ML, Sloane BF. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia (New York, N.Y.). 7: 207-23. PMID 15799821 DOI: 10.1593/Neo.04349  0.557
2004 Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biological Chemistry. 385: 1017-27. PMID 15576321 DOI: 10.1515/Bc.2004.132  0.619
2003 Brocard CB, Jedeszko C, Song HC, Terlecky SR, Walton PA. Protein structure and import into the peroxisomal matrix. Traffic (Copenhagen, Denmark). 4: 74-82. PMID 12559034 DOI: 10.1034/J.1600-0854.2003.40203.X  0.305
2002 Legakis JE, Koepke JI, Jedeszko C, Barlaskar F, Terlecky LJ, Edwards HJ, Walton PA, Terlecky SR. Peroxisome senescence in human fibroblasts. Molecular Biology of the Cell. 13: 4243-55. PMID 12475949 DOI: 10.1091/Mbc.E02-06-0322  0.357
Show low-probability matches.